Icahn Enterprises L.P. Confirms Arrangements with Brett

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Icahn Enterprises L.P. Confirms Arrangements with Brett Icahn and David Schechter

NEW YORK, Aug. 01, 2016 (GLOBE NEWSWIRE) -- In response to various inquiries, Icahn Enterprises L.P. (NASDAQ: IEP ) today confirmed that the co-manager agreements with Brett Icahn and David Schechter, co-managers of the Sargon Portfolio, expired on July 31, 2016 in accordance and in full compliance with their terms and conditions.

Carl C. Icahn, Chairman of Icahn Enterprises, stated: “For the past seven years, Brett, David and I have maintained an extremely successful and mutually beneficial portfolio management arrangement.”

It is anticipated that the co-managers will again manage a new portfolio of investments for Icahn Enterprises under new co-manager agreements in the future, the terms of which are being actively negotiated by Carl C. Icahn, Brett Icahn and David Schechter. The new co-manager arrangements have not been finalized as of this time primarily because of the shared opinion of Carl C. Icahn, Brett Icahn and David Schechter that current market valuations do not provide an opportune time to embark on large new investments. While we believe that an agreement will be reached shortly, there can be no assurance that the new co-manager agreements will be finalized by a certain time or at all.

In the interim, as discussions continue and market conditions evolve, both Brett Icahn and David Schechter have entered into consulting agreements with Icahn Enterprises under which they will exclusively provide Carl C. Icahn investment advice with respect to his investment strategy for the Investment segment and with respect to capital allocation across Icahn Enterprises’ various operating subsidiaries.

Icahn Enterprises L.P. (NASDAQ: IEP ), a master limited partnership, is a diversified holding company engaged in ten primary business segments: Investment, Automotive, Energy, Metals, Railcar, Gaming, Mining, Food Packaging, Real Estate and Home Fashion.

Caution Concerning Forward-Looking Statements

This release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, many of which are beyond our ability to control or predict. Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of Icahn Enterprises L.P. and its subsidiaries, and Icahn Enterprises’ entry into new co-manager agreements with Brett Icahn and David Schechter. Among these risks and uncertainties are risks related to economic downturns, substantial competition and rising operating costs; risks related to our investment activities, including the nature of the investments made by the private funds in which we invest, losses in the private funds and loss of key employees; risks related to our automotive activities, including exposure to adverse conditions in the automotive industry, and risks related to operations in foreign countries; risks related to our energy business, including the volatility and availability of crude oil, other feed stocks and refined products, unfavorable refining margin (crack spread), interrupted access to pipelines, significant fluctuations in nitrogen fertilizer demand in the agricultural industry and seasonality of results; risk related to our gaming operations, including reductions in discretionary spending due to a downturn in the local, regional or national economy, intense competition in the gaming industry from present and emerging internet online markets and extensive regulation; risks related to our railcar activities, including reliance upon a small number of customers that represent a large percentage of revenues and backlog, the health of and prospects for the overall railcar industry and the cyclical nature of the railcar manufacturing business; risks related to our food packaging activities, including competition from better capitalized competitors, inability of its suppliers to timely deliver raw materials, and the failure to effectively respond to industry changes in casings technology; risks related to our scrap metals activities, including potential environmental exposure; risks related to our real estate activities, including the extent of any tenant bankruptcies and insolvencies; risks related to our home fashion operations, including changes in the availability and price of raw materials, and changes in transportation costs and delivery times; and other risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission. Past performance in our Investment segment is not necessarily indicative of future performance. We undertake no obligation to publicly update or review any forward-looking information, whether as a result of new information, future developments or otherwise.

Investor Contacts: SungHwan Cho, Chief Financial Officer Peter Reck, Chief Accounting Officer (212) 702-4300

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 129

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kearney's 2025 Global Cities Report Insights

Updated Category News Views 654

Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...

Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce

Updated Category News Views 255

Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...

Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook

Updated Category News Views 55

Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...

Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism

Updated Category News Views 193

Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...

Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations

Updated Category News Views 191

Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...

Continue Reading